It is noteworthy that a phase I trial of solid tumors treated with XL228 (a small molecule inhibitor targeting Src family kinases, IGF-1R, Aurora A, and Bcr-Abl in the low nanomolar range [47]) has shown promising preliminary clinical results in melanoma and solid tumors including NSLCLC [48]. This evidence concerns the gene IGF1R and melanoma.